Find Your Study
Clinical Studies
Explore our clinical trials and find opportunities to participate in advancing medical research.
TRPC6 Inhibitor for Primary Focal Segmental Glomerulosclerosis (pFSGS)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating an oral TRPC6 inhibitor in adults and adolescents with primary FSGS or genetic FSGS related to TRPC6 gene variants. The study aims to demonstrate reduction in proteinuria and preservation of kidney function. TRPC6 inhibition targets the podocyte directly, addressing the underlying mechanism of glomerular injury.
Farabursen for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating farabursen, a novel first-in-class anti-miR-17 oligonucleotide, in patients with ADPKD at risk of disease progression. The study aims to assess whether farabursen can decrease total kidney volume (TKV) growth and slow kidney function decline. Farabursen targets miR-17, which is upregulated in ADPKD and plays a key role in cystogenesis.
POSIBIL_ESKD: Clazakizumab Cardiovascular Outcomes Study
A Phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study evaluating CSL300 (clazakizumab), an anti-interleukin-6 (IL-6) monoclonal antibody, for reducing cardiovascular events in subjects with end stage kidney disease (ESKD) undergoing maintenance dialysis. The primary endpoint is time to first occurrence of cardiovascular death or myocardial infarction. Clazakizumab targets chronic inflammation, a key driver of cardiovascular risk in dialysis patients.
ZENITH: Zilebesiran Cardiovascular Outcomes Study
A Phase 3, randomized, double-blind, placebo-controlled study evaluating zilebesiran, a novel RNA interference (RNAi) therapeutic targeting angiotensinogen (AGT), for reducing major adverse cardiovascular events. Zilebesiran is administered subcutaneously once every 6 months and has demonstrated sustained blood pressure reduction with an acceptable safety profile.
Baxdrostat/Dapagliflozin Renal Outcomes Study (BaxDuo-Pacific)
A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of baxdrostat (an aldosterone synthase inhibitor) in combination with dapagliflozin compared to dapagliflozin alone. The study aims to reduce the risk of the composite endpoint of ≥50% sustained decline in eGFR, kidney failure, or cardiovascular death in participants with CKD and high blood pressure.
Pegloticase in Kidney Transplant Patients with Uncontrolled Gout
A multicenter, open-label study evaluating the efficacy and safety of pegloticase (KRYSTEXXA) in adults with chronic gout refractory to conventional urate-lowering therapy who have undergone kidney transplantation. The primary endpoint is sustained serum uric acid reduction to <6 mg/dL during Month 6.
SNP-ACTH Gel for Primary Membranous Nephropathy
A Phase 3 superiority study comparing the safety and efficacy of SNP-ACTH (1-39) Gel versus rituximab in adults with high-risk primary membranous nephropathy. The study evaluates complete remission of proteinuria at 12 months with durability confirmation at 24 months.
Lorundrostat Open-Label Extension Study
An open-label extension evaluating long-term safety and blood pressure-lowering efficacy of lorundrostat, an aldosterone synthase inhibitor, in adults with uncontrolled hypertension who completed prior lorundrostat parent trials.
FINE-REAL: Finerenone in Routine Clinical Practice
A prospective, non-interventional study evaluating real-world treatment patterns, safety outcomes, and healthcare utilization in CKD patients with Type 2 Diabetes treated with finerenone, a novel non-steroidal mineralocorticoid receptor antagonist.